Trial Profile
A Phase II Double Blind, Randomised Controlled Trial of VEGF Inhibitor Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Liver metastases; Rectal cancer
- Focus Therapeutic Use
- Acronyms AXMUS-C
- 28 Jan 2016 Accrual to date is 76% according to United Kingdom Clinical Research Network.
- 03 Dec 2015 Accrual to date is 74% according to United Kingdom Clinical Research Network.
- 25 Oct 2015 Accrual to date is 72% according to United Kingdom Clinical Research Network.